Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« About Time | Main | Day Off »

April 1, 2010

Exelixis: Hmmmm.

Email This Entry

Posted by Derek

As a commenter here has noted, something odd happened to Exelixis stock today at about 1 PM EDT. A sudden, sustained jump of about 10% is certainly possible without a huge expenditure of money in a stock this size - but what caused it? The delayed options quotes at the CBOE show what looks like a big spike in $7.50 calls with several expiration dates. You can bet the the SEC will be watching closely to see if the company makes any announcements in the next few days. And if they do, they'll be checking to see if those option orders were placed before or after 1 PM. . .

Comments (7) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. Sili on April 1, 2010 3:34 PM writes...

Apropos of nothing, I think I need to look closer at Google Finance. I like those miniature representations of the plots in the table.

Permalink to Comment

2. Old-Timey on April 1, 2010 9:44 PM writes...

Who is going to buy Exel?

Permalink to Comment

3. VCbanker on April 1, 2010 11:19 PM writes...

Considering the layoff at Exelixis within the past 3-4 months, I'm not sure anyone's buying much of anything. It's like Sunesis: there's supposed to be great products, but no one seems to believe in them and the company's incapable of realizing the potential of its pipeline.

Permalink to Comment

4. goldilocks on April 2, 2010 11:07 AM writes...

You don't think this is the natural response to the success of Arqule's c-Met inhibitor? Exelixis has a lot riding on their own c-Met program...

Permalink to Comment

5. Anonymous on April 3, 2010 9:01 AM writes...

u still have not learned your lesson.
the SEC has more imp. stuff to attend to...
watching porn.

Permalink to Comment

6. Craig on April 5, 2010 8:28 AM writes...

The SEC are a bunch of clowns.

They're too busy going after people who break round lots into odd lots than they are going after insider traders.

They hire people out of college who have no clue about what they stock market is or does, ....but they do have criminal justice degrees!!!!!

Permalink to Comment

7. Keith on April 7, 2010 11:32 AM writes...

I think that it is about time for the populace at large to realize that all US government regulatory agencies are sleeping dogs whose sole reason for existence is to propagate the myth that "government is looking after you". The truth is that these agencies are deliberately underfunded and intimidated by Congress and its owners in the world of high finance, in order to cripple the ability of the agencies to perform their mandated duties. For that you should thank the massive bribery of our beloved and benevolent Congress people; they never see a bribe they don't like. ( You may see from my comment that I don't buy the tripe about election campaign contributions not being bribes, or that those bribes are equivalent to "protected political speech".)

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings